Rivia, a company developing a data intelligence platform for clinical trials, has raised $15 million in a Series A funding round. Led by Earlybird Venture Capital with participation from Defiant and existing backers, the capital will fuel the expansion of Rivia's platform. The company aims to unify fragmented trial data and deploy AI-driven workflows to enhance efficiency and accelerate medical research.
Confronting Industry-Wide Inefficiencies
The funding arrives as the pharmaceutical industry grapples with significant pressures, including intensifying regulatory scrutiny and declining economic returns. New FDA guidance mandates proactive risk management, pushing for innovation in trial design and technology. This evolving landscape highlights the urgent need for advanced operational tools to navigate the complexities of modern clinical research.
A core issue is the fragmented data infrastructure that underpins clinical trials, which has not kept pace with scientific advancements. Organizations often depend on manual processes to reconcile data from disparate sources like labs, wearables, and patient diaries. Incumbent systems were designed for compliance and storage, not for the interoperability required by today's multi-vendor, data-heavy trial environments.
A Foundational Approach to Data Integration
Rivia is addressing this challenge by first building a reusable intelligence layer that serves as the foundation for its platform. This data engine integrates thousands of diverse data files in real time, applying trial-specific scientific logic to harmonize the information. According to CEO Erik Scalfaro, this deliberate "data engine first" strategy is essential for creating the structure needed for reliable AI.
This foundational layer provides a unified view of trial data, enabling the creation of specialized workflows tailored to specific clinical activities. By structuring fragmented inputs into a coherent system, Rivia ensures that subsequent AI tools operate on well-organized, contextualized information. Scalfaro argues that without this initial step, any AI would produce unreliable results, underscoring the company's focus on building a robust platform.
Deploying AI Agents for Proactive Oversight
Building upon its data engine, Rivia is launching a new suite of embedded AI agents to transform trial management from reactive to proactive. The first agent, named Spark, can instantly convert natural language queries into publication-grade clinical visualizations. This tool empowers research teams to gain insights more quickly and intuitively, streamlining the data review process and facilitating better communication.
The company is also deploying next-generation agents focused on proactive data quality monitoring and operational oversight. These systems are designed to enable earlier detection of deviations, intelligently prioritize potential issues, and recommend structured, auditable actions. This shift towards "agentic AI" means the system actively assists teams in managing the complex operational layer of a trial.
Investor Confidence and Future Ambitions
The oversubscribed funding round reflects strong investor confidence in Rivia's strategic approach to a critical industry problem. Christian Nagel of Earlybird noted that Rivia has built a true intelligence layer to fundamentally improve trial execution by increasing speed and data integrity. Continued support from early investors like Speedinvest further validates the company's mission to build an essential platform for modern clinical trials.
Early adopters are reporting measurable benefits, from preventing costly errors to gaining earlier clarity on patient responses to therapies. By reducing manual work and providing faster insights, the platform helps lower trial costs and accelerate timelines for new treatments. This creates a positive outcome across the ecosystem, benefiting drug developers, research organizations, and ultimately, patients awaiting medical innovations.
With this new capital, Rivia plans to significantly expand its teams in Zurich and Boston to meet growing demand. The company's long-term vision extends to enabling more adaptive and decentralized trial designs, which become feasible with intelligent automation. Rivia's ultimate ambition is to reduce clinical trial costs substantially by replacing inefficient manual processes with scalable agentic systems to accelerate medical innovation.